Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

CONCLUSIONS: These results complement previously reported clinical benefits and support teclistamab as a promising therapeutic option for patients with RRMM.PMID:38052709 | DOI:10.1016/j.clml.2023.11.001

Source: Clinical Lymphoma and Myeloma - December 5, 2023 Category: Cancer & Oncology Authors: Thomas G Martin Philippe Moreau Saad Z Usmani Alfred Garfall Mar ía-Victoria Mateos Jes ús F San-Miguel Albert Oriol Ajay K Nooka Laura Rosinol Ajai Chari Lionel Karlin Amrita Krishnan Nizar Bahlis Rakesh Popat Britta Besemer Joaqu ín Martínez-López Source Type: research